NasdaqGM:ATRCMedical Equipment
Does AtriCure’s (ATRC) Push Toward Positive EBITDA Recast Its Long‑Term Investment Narrative?
In January 2026, AtriCure reported preliminary 2025 results and issued 2026 guidance, projecting approximately US$600 million to US$610 million in revenue and expecting positive adjusted EBITDA, net income, and cash flow, while also highlighting new product launches and completion of enrollment in a key clinical trial.
The company simultaneously extended its asset-based revolving credit facility by three years on improved terms, lowering interest costs and adding flexibility that could...